AbbVie Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.

Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending September 29, 2021 was $-1.2 Billion (a -65.3% decrease compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) increased by 84.49%
  • Annual Repayment/Issuance of Debt (Net) for 2020 was $-2.7 Billion (a -110.47% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $25.8 Billion (a 709.75% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2018 was $3.19 Billion (a -159550.0% decrease from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending September 29, 2021 was $-6.58 Billion (a 7.13% increase compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -123.32% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
29 Sep '21 29 Jun '21 30 Dec '20 29 Sep '20
$-6.58 Billion $-6.14 Billion $25.7 Billion $28.2 Billion
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of AbbVie Inc.

Most recent Repayment/Issuance of Debt (Net)of ABBV including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of AbbVie Inc.

AbbVie Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-1,201.0 $-3,461.0
2020 $-1,269.0 $-651.0 $-763.0 $-2,703.0
2019 $28,417.0 $1,227.0 $-197.0 $-3,200.0 $25,823.0
2018 $-315.0 $3,446.0 $138.0 $-40.0 $3,189.0
2017 $-407.0 $395.0 $-7.0 $17.0 $-2.0
2016 $235.0 $-495.0 $5,860.0 $-6.0 $5,519.0
2015 $-357.0 $761.0 $16,075.0 $144.0 $16,623.0
2014 $107.0 $50.0 $248.0 $-410.0 $-5.0
2013 $2.0 $1.0 $-3.0 $-601.0 $-601.0
2012 $15,586.0 $15,586.0
2011 $-10.41 $-2.92 $13.27 $-21.03
2010 $-32.08

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.